Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc.

NTHI·NASDAQ

$4.35

-4.2%
HealthcareBiotechnology

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

At a Glance

Live Snapshot
Market Cap$86.98M
EPS-3.2300
P/E Ratio-1.35
Earnings Date06/03/2026

nthi

Net Cash Provided by Financing Activities

Last Annual Value

20.86M

3-Year CAGR

141%

5-Year CAGR

142%

10-Year CAGR

56%

Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

NTHI · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
20.86M
153.6%142.3%N/A 
25.61M
-22.0%0.1%13.5%
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
215.63M
490.9%-20.1%N/A
OABI logo
OmniAb, Inc.
NASDAQ:OABI
27.91M
N/A23.5%N/A
86.30M
57.0%48.2%9.7%
174.67M
132.9%26.9%102.2%
77.43M
N/A4.9%16.5%
9.89M
-39.2%N/AN/A
70.75M
69.3%16.6%70.7%
82.72M
N/AN/A82.0%
88.33M
24.1%N/AN/A
Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc. Fair Value Envelope

NTHI · NASDAQ

Our analysis suggests that NTHI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.35, this represents a potential HIDDEN relative to our calculated worth for Neonc Technologies Holdings, Inc..

Intrinsic Value
Current Price: $4.35